Bayer's Seed and Pharma Pipelines Gain Momentum as June Court Deadlines Tighten the Screw

Bayer reports strong crop science growth and pharma wins in China and ophthalmology, but Monsanto litigation costs drain cash, with free cash flow negative and debt rising.

The German conglomerate is weaving a narrative of two speeds. On one side, its crop science division is rolling out a fresh generation of hybrids and soybeans, while the pharma arm scores regulatory progress in China and a billion-dollar acquisition in ophthalmology. On the other, the legal hangover from the Monsanto takeover continues to drain cash and dominate the calendar, with two pivotal deadlines falling in the next 60 days.

Crop Science’s five-year roadmap is ambitious. Management has targeted more than €1 billion in cost savings, €3.5 billion in additional revenue, and €1.5 billion in extra cash generation. For the current fiscal year, Bayer reaffirmed guidance for 1–4% sales growth in the division and an operating margin of 20–22% — a notable increase from the 19.4% recorded last year. The engine of that expansion is a revamped seed portfolio. In the United States, 75% of this year’s corn hybrids come from introductions made in the past three years, including short-stature Preceon corn and Vyconic soybeans. More biotech traits are slated for the U.S. and Brazil over the next five years. On the cost side, the company is closing three global sites, exiting Frankfurt, consolidating activities in Monheim and Dormagen, pruning 200 low-margin products from the portfolio, and withdrawing regulatory applications in ten Asian countries to sharpen its crop-protection strategy.

Pharma is also seeing fresh momentum. In April, China’s NMPA accepted an application for Asundexian, an anti-stroke candidate that cut the risk of recurrent ischemic stroke by 26% versus placebo in the phase?III OCEANIC-STROKE trial, without raising bleeding risk. The drug is under accelerated review in China and holds FDA fast?track status in the U.S. — though the addressable market for secondary stroke prevention is estimated at $3–4 billion, far smaller than the atrial fibrillation opportunity Bayer previously pursued with the same compound. Meanwhile, in early May, Bayer announced the full acquisition of Perfuse Therapeutics for up to $2.45 billion. The deal secures PER?001, a phase?II endothelin receptor antagonist for glaucoma and diabetic retinopathy. With an upfront payment of $300 million and up to $2.15 billion in milestones, it is Bayer’s largest acquisition since AskBio in 2020. The rationale is clear: Eylea, Bayer’s biggest eye?care product with roughly €3.1 billion in sales, is losing velocity, and PER?001 offers a pipeline replacement.

But the operational progress is being eclipsed by the cost of litigation. First?quarter results showed the tension clearly. Revenue reached €13.4 billion, a currency?adjusted gain of 4.1%, and Crop Science’s EBITDA jumped 17.9%, pushing its margin to 39.9%. Yet free cash flow was negative €2.3 billion, driven by roughly €2 billion in outflows for glyphosate and PCB settlements. Net financial debt rose to €32.5 billion. For the full year, Bayer expects free cash flow between negative €2.5 billion and negative €1.5 billion — a figure that already incorporates legal payouts of around €5 billion.

That financial overhang makes the next few weeks critical. The opt?out deadline in the glyphosate class?action settlement process is June 4, and the U.S. Supreme Court is expected to rule on a separate appeal within roughly 60 days. Management has called 2026 a “key year” for containing the glyphosate liability. The market is watching closely: the stock closed Friday at €37.72, down 0.97% on the day. It has gained 2% over the past week but dropped 7.41% over the last 30 days. At current levels, the share price is about 23% below its 52?week high of €49.17, though it has still recovered roughly 65% year over year. Technically, the stock sits just below its 50?day moving average of €38.84 and barely above the 200?day average of €35.12 — a zone analysts view as a support floor, provided no fresh legal shocks emerge.

The twin deadlines will determine whether Bayer can translate pipeline momentum into financial breathing room. Crop Science is delivering, pharma is restocking, but the legal albatross still controls the altitude.